Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), a specialty pharmaceutical company, is committed to providing prescription drugs designed to address central nervous system (CNS) disorders. Currently, the company is building a core portfolio of both marketed and development-stage products that attend to substantial, but unmet medical needs. Questcor’s aim is to develop and commercialize their own proprietary products, while staying open to partnering concepts to leverage assets and further build its portfolio. For further information, visit the Company’s web site at www.questcor.com.
- 17 years ago
QualityStocks
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Receives Court Approval for Shareholder Claim Settlement
Vision Marine Technologies (NASDAQ: VMAR) announced that on Aug. 13, 2025, the New York State…
-
QualityStocksNewsBreaks – GlobalTech Corporation (OTCID: GTLK) Posts 23% Revenue Growth in Q2 2025 on Strong Telecom Performance
GlobalTech (OTCID: GTLK), a technology holding company specializing in artificial intelligence and big data solutions,…
-
QualityStocksNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Narrows Q2 Loss 66% as E-Commerce Growth Offsets Healthcare Headwinds
NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company in healthcare and technology,…